Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | PLK1 | P53350 | 3/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.49 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 7/20 | 0.46 |
| ▸ | IGF1R | P08069 | 3/20 | 0.46 |
| ▸ | MAPK7 | Q13164 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.45 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202819 | 0.89 | PLK1 (0.63) | PLK1PLK3PLK2LRRK2MAPK7 | |
| SCHEMBL1204311 | 0.86 | GSK3B (0.71) | GSK3AGSK3BPLK1TNK2 | |
| SCHEMBL1202852 | 0.84 | PLK1 (0.64) | PLK1PLK3PLK2MAPK7BRD4 | |
| SCHEMBL1203596 | 0.84 | GSK3A (0.58) | GSK3AGSK3BPLK1PLK3PLK2 | |
| SCHEMBL1203981 | 0.84 | PLK1 (0.63) | PLK1PLK3PLK2MAPK7BRD4 | |
| SCHEMBL4079437 | 0.77 | LRRK2 (0.55) | GSK3AGSK3BPLK1LRRK2MAPK7 | |
| SCHEMBL1203373 | 0.77 | PLK1 (0.59) | PLK1PLK3PLK2BRD4 | |
| SCHEMBL1203592 | 0.76 | RAD52 (0.59) | PLK1PLK3PLK2BRD4 | |
| SCHEMBL3667130 | 0.76 | GSK3A (0.52) | GSK3AGSK3BPLK1PLK3PLK2 | |
| SCHEMBL4080993 | 0.76 | LRRK2 (0.59) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | claimed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| EP-2610256-B1 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LTD (GB) | 2016-04-27 | — | — | EP | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | TETHRA BIOSCIENCES INC. | 2014-03-06 | — | — | US | disclosed |
| EP-2205603-B1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2014-01-15 | — | — | EP | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | GSK3A 720/4885GSK3B 713/4885PLK1 355/4885 |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | GSK3A 771/4885GSK3B 740/4885PLK1 349/4885 |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | GSK3A 509/4885GSK3B 485/4885PLK1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.